Precision medicine and data
Prenosis Sepsis ImmunoScore
FDA De Novo-authorized AI/ML software that assigns adult emergency department or hospital patients to sepsis risk categories within a clinician-reviewed workflow.
Last updated: June 11, 2026
Back to directoryCancerIQ medical AI product profile
Precision oncology platform for scaling hereditary cancer risk assessment, genetic testing workflows, patient navigation, and genomics-driven cancer prevention programs.
Precision medicine and data
Best fit
Cancer prevention and genetics programs that need an EHR-connected workflow to collect family-history data, identify eligible patients, route navigation, and monitor follow-through.
- Primary use case
- Digital cancer risk assessment, patient intake, hereditary cancer screening, genetic testing workflow support, patient navigation, and oncology innovation enrollment
- Audience
- Health systems, oncology programs, breast centers, genetics clinics, primary care networks, nurse navigators, and population-health teams expanding hereditary cancer risk assessment
- Risk level
- High
- Pricing signal
- Enterprise pricing is not public; request current platform, integration, implementation, genetic-testing workflow, support, privacy, security, and services terms.
- Official sources
- 5 official sources
Compare within workflow: Precision medicine and data · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating CancerIQ as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as clinical decision support and precision oncology workflow infrastructure unless a specific deployment makes diagnostic, testing, or treatment claims; verify risk-model logic, guideline basis, clinician oversight, and local genetics governance. |
|---|---|
| Privacy | Review platform privacy and contracted BAA terms for PHI, family-history, genetic-risk, test-ordering, EHR, navigator, analytics, support, subprocessors, retention, de-identified data use, and patient-rights handling. |
| Evidence | Use vendor research and published workflow studies as starting points, then measure local eligibility capture, genetic counseling or testing uptake, patient comprehension, equity, adherence, false positives, and missed high-risk patients. |
| Workflow | Best governed as provider-directed cancer-risk navigation with documented patient consent, genetics review pathways, EHR integration testing, result reconciliation, referral queues, guideline-update monitoring, and patient communication controls. |
Where CancerIQ fits
CancerIQ describes an integrated intelligence platform for health systems scaling genomics and oncology innovation, including screening, risk assessment, and patient navigation. Its platform terms describe a digital healthcare platform used by providers to collect patient data, assess hereditary cancer risk, and support clinical decision making; its platform privacy policy says CancerIQ processes PHI as a HIPAA Business Associate under a provider BAA. CancerIQ research pages point to peer-reviewed work on digital cancer risk assessment and genetic testing uptake.
Not for: Autonomous diagnosis, independent treatment selection, direct-to-consumer genetic counseling, unsupported clinical decisions, or deployments without provider oversight, BAA review, local genetics governance, and clear patient consent.
What to verify before using CancerIQ
- Which CancerIQ modules are in scope, including patient questionnaires, hereditary cancer risk assessment, provider dashboards, navigator workflows, specialist review, analytics, virtual care, EHR integration, or registry functionality.
- How risk logic, guideline mapping, eligibility criteria, patient education, automated test ordering, result handling, navigation tasks, and follow-up recommendations are reviewed by clinicians and genetics staff.
- Platform privacy policy, BAA terms, HIPAA role, PHI processing, family-history and genetic data retention, subcontractor access, de-identified analytics, EHR interfaces, and whether provider policy controls patient rights handling.
- Local validation for patient population, family-history completion, genetic testing eligibility, referral completion, testing uptake, false reassurance, over-referral, equity across languages and sites, and downstream screening adherence.
- How CancerIQ output is documented in the EHR, reconciled with genetic test results, routed to oncology or genetics teams, and monitored for guideline changes or risk-model updates.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.canceriq.com
- www.canceriq.com / research-partnerships
- www.canceriq.com / terms-of-use-agreement
- www.canceriq.com / privacy-policy
- go.canceriq.com / research-workflow-that-includes-digital-platform-increases-genetic-testing-uptake
Related medical AI products
Precision medicine and data
Cytovale IntelliSep
FDA 510(k)-cleared sepsis test that runs on the Cytovale System and returns an IntelliSep Index band for adult ED patients with signs or suspicion of infection.
Precision medicine and data
Anumana ECG-AI
Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.
Precision medicine and data
Eko Health SENSORA
FDA-cleared cardiovascular detection platform that pairs Eko digital stethoscopes with AI-supported ECG and heart-sound analysis for supervised point-of-care screening.